Interleukin 10 pretreatment protects target cells from tumor- and allo- specific cytotoxic T cells and downregulates HLA class I expression by unknown
Brief De~nitive  Report 
Interleukln  10 Pretreatment Protects Target Cells 
from Tumor- and Allo-specific  Cytotoxic T  Cells and 
Downregulates  HLA Class I Expression 
By  Masanori  Matsuda,* [I  Flavio  Salazar,*  Max  Petersson,* 
Giuseppe  Masucci,~  Johan  Hansson,$  Pavel  Pisa, S Qian-Jin  Zhang,* 
Maria  G.  Masucci,*  and  Roll  Kiessling*$ 
From *Microbiology and Tumor Biology Center, Karolinska Institute, S-171 77 Stockholm; and 
*Department of Oncology, Radiumhemmet, and SDepartment of Medicine, Karolinska Hospital, 
S-171 76, Stockholm, Sweden; and UDepartment of Surgery, Yamanashi Medical College, 
Yamanashi, 409-38, Japan 
Summary 
Interleukin 10 (IL-10) is a cytokine with a variety of reported effects including inhibition of 
monocyte major histocompatibility complex (MHC) class  II-dependent antigen presentation, 
type 1 helper T cell cytokine production, and inhibition of T cell proliferation. Herein we report 
the  effect of IL-10  pretreatment  on antigen presentation  to  tumor-  and allo-specific CD8 + 
cytotoxic T  lymphocytes (CTL). Prior incubation of human melanoma cells with recombinant 
IL-10 (rlL-10) for 48-72 h resulted in a dose-dependent, up to 100% inhibition, of autologous 
CTL-mediated, HLA-A2.1-restricted, tumor-specific lysis. Allo-specific CTL cytotoxicity against 
Epstein-Barr virus-transformed lymphoblastoid cell lines (LCL) was also inhibited, demonstrating 
a protective effect also on lymphoid calls.  In contrast,  IL-10 pretreatment  of allogeneic LCL 
or K562 targets had either no effect or slightly enhanced cytotoxic activity mediated by freshly 
isolated or IL-2-activated natural killer cells. Flow cytometric analysis with monoclonal antibodies 
against HLA-A2, or nonpolymorphic determinants of MHC class I proteins, revealed a 20-50% 
reduction in call-surface expression,  whereas  intercellular  adhesion  molecules  1,  and 2,  and 
lymphocyte function-associated antigen 3 levels were not affected. In addition, relative to untreated 
target cells, IL-10 pretreated tumor ceils were unaltered in their capacity to affect CTL-mediated 
lysis by cold target inhibition, demonstrating that the effect of IL-10 is unrelated to the initial 
binding of CTL to their targets.  These results are compatible with an effect of IL-10 on the 
MHC class I antigen presentation pathway, and suggest a novel mechanism of immune tolerance, 
based on escape from CTL-mediated tumor and allo-transplant  rejection. 
I 
L-10 was discovered because of its ability to suppress cytokine 
expression by type 1 helper T  cells (Thl) and NK cells 
(1). More recently, it has been shown to have pleitropic im- 
munosuppressive effects. In vitro, IL-10 also blocks monocyte- 
dependent T  cell proliferation (2),  inhibits monocyte class 
II MHC expression (3),  the upregulation of B7 on mono- 
cytes (4), and monocyte-associated production of nitric oxide 
and killing of parasites (5). 
IL-IO is produced by a variety of cell types, including T 
cells, B cells, and macrophages (6, 7). Higher levels of human 
IL-10 were produced by Th2 than Thl clones (8), and several 
human carcinoma lines, freshly isolated tumor biopsies, pa- 
tient serum, and ascites fluid express or contain IL-10 (9-11). 
These observations suggest that the presence of IL-IO may 
be a common feature of several types of human tumors-a 
finding of potential importance regarding adverse effects on 
the host immune response. 
In view of these findings, and since there is evidence sug- 
gesting that tumors can be rejected by infiltrating CTL, we 
analyzed the effect that IL-10 pretreatment of tumors had 
on their sensitivity to MHC class I-restricted CTL. Our results 
show that pretreated melanoma and human B cell lines were 
impervious to otherwise lethal CTL-a phenomenon paral- 
leled by a decrease in target cell surface MHC class I levels. 
In contrast, susceptibility to NK cell-mediated cytotoxicity 
was,  at times,  slightly enhanced. 
Materials  and Methods 
Production of  Melanoma Cell Lines and Tumor-  and Allo-specific CTL 
Lines.  Human metastatic  melanoma specimens, resected at the 
Karolinska Hospital Department of Oncology, were processed by 
enzymatic digestion as described (12). The melanoma line 397 Mel, 
kindly provided by Dr. Paul R_obbins  (National Institutes of Health, 
Bethesda, MD) was used as an HLA-A2.1 negative control 
To produce a tumor line, adherent calls from the surgical spec- 
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tamine, 100 U penicillin/ml,  and 100/zg/ml streptomycin). The 
tumor cells were analyzed by staining with the mAb anti-S-100/ 
horseradish peroxidase (HRP) and anti-human-melanoma/HILP 
clone HMB45  (DAKO,  Glostrup,  Denmark).  All  tumors were 
typed, using the mAb HB 54 for the presence of HLA-A2.1, by 
FACScan  |  analysis (Becton Dickinson & Co., Mountain View, CA). 
Tumor-specific CTL lines were obtained essentially as described 
(13). Single cell suspensions from metastatic lymph nodes were cul- 
tured in serum-free medium (AIM-V,  Gibco, Paisley, UK),  sup- 
plemented with 10 IU human rlI~2/ml (kindly suppled by Dr. Paul 
Simon, DuPont, Glenotden,  PA). The cultures were stimulated every 
10-14 d with irradiated tumor cells (one tumor cell to 20 T cells) 
by the appropriate autologous melanoma cell line.  Cytotoxic ac- 
tivity against the K562 and HLA-A2.1 § lymphoblastoid cell lines 
(LCL) was used to assess specificity. CTL clones were obtained from 
a line established from a patient (KH) by standard limiting dilu- 
tion. Allo-specific CTL lines were produced as described above for 
the production of tumor-specific lines, but PBMC of healthy HLA- 
A2.1-  donors and irradiated allogeneic HLA-A2.1 § PBMC were 
used as responder and stimulator cells, respectively. 
Treatment of Tumor Cells with rlL-lO.  Melanoma or LCL were 
cultured in AIM-V serum-free medium containing 50-200 U human 
rlL-10/ml (sp act: 107 U/mg; DNAX, Palo Alto, CA; a kind gift 
from Dr. A. Ogarra) for 2-3 d, unless  otherwise indicated. Con- 
trol cultures in AIM-V medium alone were set up in parallel.  The 
rlbl0-treated  tumor cells were extensively washed during  SlCr 
labeling (which was performed before exposure to CTL effector 
cells). As a specificity control for the effect of rib10, medium con- 
taining rib10 (100 U/ml) was immunoadsorbed to beads (Dyna- 
beads; Dynal, Oslo, Norway) coated with the anti-human Ibl0 
mAb 19F1 (American Type Culture Collection [ATCC], RockviUe, 
MD) (14), or with control beads without  this mAb. 
mAhs  and FACS  |  Analysis.  The  antibodies  W6/32  (anti- 
nonpolymorphic part of HLA class I), and HB 54 (anti-HLA-A2.1) 
were obtained from the ATCC. The mAb specific for CD28 (9.3) 
was kindly provided courtesy of Bristol-Myers Squibb Pharmaceu- 
tical Research Institute (Seattle, WA). The lib 54 and the 9.3 mAbs, 
purified via protein-A, were used at a concentration of 5/~g/ml 
when added to cytotoxicity assays in blocking experiments. The 
antibodies LB-2 (intercellular adhesion molecule 1 [ICAM-1]) and 
BB-1 (B7) were purchased from Becton Dickinson & Co.  Cells 
treated with mAbs were stained with a secondary FITC-coupled 
rabbit anti-mouse Ig (Dakopats, Glostrup, Denmark),  and ana- 
lyzed using a FACScan  |  flow cytometer (Becton Dickinson & Co.). 
Cytotoxicity.  A 6 h SlCr-release assay was used to measure cyto- 
toxic activity of CTL or NK cells against melanoma, LCL, or K562 
cells. All samples were run in triplicate. Specific lysis was calcu- 
lated according to the formula: percent specific lysis =  100  x  [(ex- 
perimental cpm -  spontaneous cpm)/(maximum cpm -  sponta- 
neous cpm)]. 
Results 
We studied the effect of rlL-10 pretreatment on the sensi- 
tivity of human melanoma cells to lysis by autologous tumor- 
specific CTL lines derived from tumor infiltrating lympho- 
cytes (TIL). These CTL showed partial cross-reactivity against 
other  HLA-A2.1 + melanoma targets,  but  did not  kill  au- 
tologous LCL cells (data not shown).  In addition,  cytolytic 
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Figure  1.  Ibl0 pretreatment renders melanoma cells insensitive to lysis by tumor-specific CTLs. (A and B) Tumor-specific  CTL lines, restricted 
by HLA-A2.1 as inferred from blocking by addition of the mAb HB 54, were generated from patient DL (A) and KH (B). CTbmediated cytotoxicity 
against pretreated autologous melanoma lines (48 h in medium alone or in medium containing 50, 100, or 200 U/ml or rlL-10), was assessed by 6-h 
slCr-release assay. The effect of adsorbing I1-10 from medium containing 100 U/m1 with beads coated with a mAb specific for IL-10 (19F1) before 
the incubation with melanoma targets is shown. The NK target K562 was included as a control. One representative experiment of three for each 
CTL target combination is shown. (C) A CD8 + CTL clone was isolated from KH and tested against autologous mdanoma cells which were either 
untreated or pretreated with rlL-10 (100 U/ml for 48 h), or with an anti-HLA-A2.1 mAb (5 #g/ml) included during the assay. One representative 
experiment out  of two is shown. 
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tivity against the NK target K562 (Fig.  1, A  and B). After 
rlL-10 pretreatment for 48 h, but not for 24 h or less (data 
not shown), a dose-dependent decrease in the susceptibility 
of DL and KH melanoma cells to lysis by autologous CTL 
was seen. Inhibition of cytotoxicity increased as a function 
of dose from 50 to 100%, with maximum inhibition at the 
highest tested dose of 200 U  rlL-lO/ml (Fig.  1, A  and B). 
IL-IO preincubation did not effect the viability of the mela- 
noma cells, as indicated by unaltered spontaneous release of 
SlCr and by trypan blue exclusion.  Removal of the rlL-10 
from the preincubation medium with an anti-IL-10-specific 
mAb abrogated a large part of the tumor-protective effect 
(Fig. 1 A). Although an HLA-A2.1-restricted CD8 + T cell 
done, isolated from the KH line, was unable to lyse rIL- 
10-pretreated autologous melanoma ceils, it was highly cyto- 
toxic against nontreated tumor cells (Fig. 1 C). This obser- 
vation excluded the possibility that the presence  of a low 
number of CD4 +  cells  in  the  polyclonal CTL  line was 
necessary for IL-10-mediated tumor cell protective effects, 
and confirmed that CD8 + cells were responsible for the ob- 
served cytotoxic activity. 
The question of whether rlL-10 would also protect target 
cells of hematopoietic origin from class I-restricted CTL- 
mediated lysis was investigated by using EBV-transformed 
LCL as target cells. An aUo-specific CTL line,  which was 
partly inhibited by addition ofa mAb specific for HLA-A2.1 
but not with a mAb against CD28, was used for this pur- 
pose. Preincubation of LCL (KH and GA) with rlL-10 for 
48 h (100 U/ml) resulted in decreased sensitivity to aUo-specific 
CTL. The magnitude of this effect was similar to that seen 
with melanoma-specific  cytotoxicity (data  not shown). 
We also investigated whether IL-IO preincubation would 
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Figure 2.  Surface  expression of 
MHC class I is reduced by I1.-10 
pretreatment. DL melanoma cells 
(A) and KH LCL (B) were cultured 
in 100 U/ml of rlbl0 for 48 h, or 
in medium only, and analyzed by 
FACScan  |  after indirect staining 
with mAbs against a monomorphic 
determinant of HLA class I (W6/ 
32), against HLA-A2.1 (HB 54), the 
adhesion molecules  ICAM-1 (LB-2), 
ICAM-2 (CBR-IC2/2), LFA-3 (TS 
2/9)  or the  B7 (BB-1) accessory 
molecules, as indicated. and from IL-2-activated NK cells with LAK activity. Either 
no effect or sometimes a slight increase in the susceptibility 
to lysis by purified allogeneic NK cells or IL-2-activated killer 
cells was seen after preincubation of the KH LCL with 100 
U rIL-10/ml for 48 h. This treatment failed to alter the sus- 
ceptibility ofK562 cells to either NK or IL-2 activated killer 
cell-mediated cytotoxicity (data not  shown). 
As the activity of both the tumor-  and the allo-specific 
CTL lines was MHC class I restricted, we tested the possi- 
bility that the observed effect of IL-10 on CTL lysis would 
correlate with decreased cell surface expression of these pro- 
teins. Flow cytometric analysis, by indirect staining  with mAb 
against HLA-A2.1 or mAb against nonpolymorphic deter- 
minants of MHC class I, of IL-10-pretreated melanoma and 
LCL revealed a 20-50%  decrease of HLA-A2.1,  and total 
MHC class I expression (Fig.  2). This decrease appeared to 
be more pronounced for HLA-A2.1 than  total MHC class 
I expression (Figs.  2 and 3), and was dose dependent (Fig. 
3 A). We noted that although pretreated melanoma cells (with 
200 U  IL-10/ml) were often totally protected from lysis by 
tumor-specific CTL, they retained 50% or more of their sur- 
face MHC class I (e.g., melanoma DL Fig.  1 A  versus Fig. 
3 A). It is notable that time-kinetic analysis showed that shorter 
time periods (<24 h) of exposure to rlL-10 was not protec- 
tive (shown for the KH LCL in Fig. 3 B). In addition, after 
>5 d of culture, MHC class I levels returned to normal, per- 
faaps because of consumption of the IL-10.  No alterations 
in cell-surface expression of the adhesion molecules ICAM-1 
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Figure  3.  Dose dependency and time-kinetic analysis of the rlbl0 in- 
duced downregulation of MHC class I expression. (A) DL melanoma cells 
were cultured in medium containing the indicated doses of rlL-10 for 48 h, 
or in medium alone, and analyzed by FACScan  ® after indirect staining 
with mAbs against the monomorphic determinant of HLA class I (W6/32) 
or against HLA-A2.1 (HB 54). The same melanoma cells used in this ex- 
periment were also used in cytotoxicity assays shown in Fig. 1 A. (B) An 
EBV-transformed B cell line from patient KH was cultured in rlL-10 (100 
U/ml) for the indicated time intervals and tested for expression of MHC 
class I  or HLA-A2.1. 
(LB-2), ICAM-2 (CBR-IC2/2),  or LFA-3 (TS 2/3) on ei- 
ther melanoma or LCL was seen as a result of IL-10 preincu- 
bation (Fig.  2). 
It was recently shown that  IL-10 inhibited macrophage 
costimulatory activity by selectively inhibiting the upregula- 
tion of B7 expression (4). To initiate the investigation of al- 
ternative mechanisms for IL-10-mediated protective effects, 
we examined B7 levels on the KH LCL target after incuba- 
tion with rlL-10 for 3 d. A  marginal  decrease in B7 levels 
was observed (Fig. 2 B). Anti-CD28 mAb did not block lysis 
(data not  shown),  indicating  that lysis of the KH LCL by 
allo-specific  CTL was not dependent on CD28-B7 interac- 
tion, and B7 was not expressed by our melanoma lines (data 
not shown). It therefore appeared unlikely that downregula- 
tion of B7 expression was responsible for decreased sensitivity 
to CTL-mediated lysis. 
We also tested the effect of IL-10 pretreatment  of tumor 
cells in cold target  inhibition  assays. No significant  differ- 
ences were found between IL-10 pretreated and untreated au- 
tologous DL melanoma cells in their ability to inhibit specific 
lysis,  with both types of competitors giving a comparable 
degree of dose-dependent inhibition (Fig. 4). This "cold target 
competition" was, as expected, HLA-A2.1 restricted and an- 
tigen specific, since an HLA-A2.1 ÷ melanoma and an HLA- 
A2.1 ÷  LCL  did  not  inhibit  cytotoxicity,  regardless  of 
whether these had been pretreated with rlL-10. These results 
therefore argue for the possibility that IL-10-treated target 
cells effect postbinding events involved in CTL-mediated lysis, 
and further argue against IL-10-induced changes in nonspecific 
adhesion molecules as the explanation of the observed pro- 
tection. 
Discussion 
IL-10 has been shown to suppress the induction of T cell 
responses by acting at several levels including inhibition  of 
monocyte MHC class II expression, upregulation  of acces- 
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Figure  4.  Unlabeled  rlL-10- 
treated tumor cells are not supe- 
rior  inhibitors  of  melanoma- 
specific  cytotoxicity.  Unlabeled 
tumor cells were added to a con- 
stant number of 51Cr-labeled DL 
melanoma targets, and the CTL 
line from DL was used as effector 
cells at an E/T ratio of 30:1. As 
unlabeled "cold" competitors, the 
DL melanoma, the HLA A2.1 + 
LCL  from patient KH,  and the 
HLA  A2.1-  melanoma  (397 
Mel), cultured with  rlL-10  (100 
U/ml) or with medium only for 
3 d, were used at the ratio of la- 
beled  DL  to  cold  competitor 
shown. When rlL-10-treated DL 
cells  were  labeled  and  used  as 
targets,  they showed a 45%  de- 
crease in sensitivity to lysis in the 
same experiment (data not shown). 
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target cells insensitive to MHC class I-restricted tumor- and 
allo-specific  CTL lysis. This phenomenon was initially ob- 
served on melanoma targets, but the observation that EBV- 
transformed B cell lines are also protected by lysis by CTLs 
shows that IL-10 exerts this effect on cells of hematopoetic 
origin as well. This is in contrast to the inhibitory effect of 
IL-10 on MHC class II expression previously shown to be 
effective on monocytes but not on LCL (3). 
The inhibition ofCTL lysis induced by rlL-10 was associated 
with a moderate decrease in the expression of HLA class I, 
which to our knowledge, is the first example of a cytokine 
with this effect. A  small but detectable decrease in MHC 
class I expression was reported after culture of normal mouse 
B cells with rlL-10 for 22 h  (15),  although this effect was 
not further analyzed by the authors. In our study, 2-3 d of 
in vitro culture with rlL-10 under serum-free conditions was 
required to detect a clear reduction in MHC class I levels, 
which might explain why others have not observed this effect. 
Alternatively, only melanoma and transformed B cells, as used 
in our study, but not normal B cells (15),  are sensitive  to 
this effect. 
Our findings suggest that production of IL-10 by tumor 
and/or by tumor-infiltrating host cells might serve as a mech- 
anism by which tumor progression occurs in the face of host 
CTL that are potentially lytic for tumor cells.  Other im- 
munosuppressive mechanisms acting locally within the tumor 
as well as in the peripheral blood of patients with human 
colorectal carcinomas include recently described alterations 
in signal-transducing ~" chains of CD3 and CD16 molecular 
complexes on T  and NK cells (16). The possibility that lo- 
cally secreted cytokines within tumors contribute to down- 
regulation of lymphocyte functions is presently under inves- 
tigation. 
A variety of human solid and hematopoietic human tumor 
lines,  including 38% of melanoma lines and 70% of colon 
carcinomas, were previously reported to produce IL-10 (9). 
Furthermore, IL-10 mRNA was detected in biopsies from 
ovarian carcinomas (10)  and in  freshly excised  melanoma 
metastases (17). In addition, high levels oflL-10 were found 
in sera and ascites of patients with ovarian carcinomas (11). 
The ubiquitous expression of IL-10 in human tumors might 
therefore contribute to the often observed downregulation 
of MHC class I expression in tumors. 
The finding that rIL-10-pretreated tumor cells were not 
superior cold target inhibitors than untreated cells tend to 
exclude the possibility that adhesion molecules involved in 
initial effector/target binding are affected by rlL-10-a con- 
clusion also supported by our FACScan |  analysis of adhesion 
molecules. This experiment also argues against the possibility 
that IL-10 induces the secretion of rapidly acting factors that 
block CTL activity. Therefore, a mechanism involving changes 
within the antigen presentation machinery of the target cells 
appears likely. The unaltered or even increased susceptibility 
to  NK  lysis  of pretreated  targets  is  consistent  with  this 
proposal. 
The total abrogation of CTL sensitivity in the presence 
of significant residual levels of class I antigens argues against 
a decrease in MHC class I expression on the tumor targets 
as the sole mechanism responsible for resistance to CTL lysis. 
One possibility would be that HLA molecules on the surface 
of IL-10-treated tumor calls may not contain the relevant 
T cell epitope in adequate amounts to trigger CTL lysis. Thus, 
investigations on the effect of rIL-10 on the TAP-1 and -2 
molecules as well on the proteasome complex are presently 
in progress. Perhaps reduced levels of MHC class I antigens 
arise as an indirect consequence of an inhibition of the an- 
tigen processing machinery, leading to a deprived pool of 
peptides necessary for MHC class I assembly and cell surface 
expression. A posttranscriptional regulation of MHC class 
I expression has been postulated to explain the downregula- 
tion of these molecules in cervical carcinomas (18). The down- 
regulation of peptide-transporter molecules TAP-1 and -2 ac- 
companied by loss  of class I MHC  expression as recently 
reported in situ in cervical carcinomas and in small cell lung 
carcinoma cell lines is consistent with this proposal (19, 20). 
As IL-10 did not affect and even slightly enhanced tumor 
sensitivity to lysis by NK cells, expression of IL-10 may have 
the opposite effect on NK-mediated tumor surveillance- 
inhibiting rather than promoting tumor growth. The previ- 
ously observed finding of reduced growth of tumors trans- 
fected with an IL-10-expressing construct in T cell-deficient 
SCID and nude mice, known to have high NK activity, is 
compatible with this possibility (21). Further studies in an- 
imal models aimed at dissecting the effect of IL-10 on the 
different components of anti-tumor responses therefore seem 
worthwhile pursuing. Recently, high levels of IL-10 produc- 
tion in vivo were found to be associated  with tolerance in 
SCID patients transplanted with HLA-mismatched hemato  o 
poietic stem cells (22).  Our finding that IL-10 also protects 
target cells from allo-spedfic CTL might therefore have a wider 
implication in relation to tolerance to HLA-mismatched al- 
lografts. 
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